Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer
Dr. Sara Nunnery, director of breast cancer research at Tennessee Oncology, discusses the evolving classification of HER2-low and HER2-ultralow breast cancer, and the clinical implications of the DESTINY-Breast06 trial. She explains how precise pathology reporting is key to identifying eligible patients and offers insights into how Enhertu (trastuzumab deruxtecan) is changing treatment decisions in HR-positive, HER2-low metastatic breast cancer. #breastcancer #her2 #enhertu #oncology #cancerresearch #medtwitter
▶︎
Breast Cancer: MUST know details (ER, PR, HER2, Ki67, etc)
▶︎
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification
▶︎
Understanding Enhertu for HER2-Low & HER2+ Metastatic Breast Cancer
▶︎
Lump to Breast Cancer - Alison | Triple Positive Breast Cancer | The Patient Story
▶︎
Breast Cancer Recurrence: Am I Cured?
▶︎
My Urgent Breast Cancer Screening Experience! Age 31💖
▶︎
Defining HER2-Low and HER2-Ultralow Breast Cancer
▶︎
HER2-Low Breast Cancer: Treatment Options and What You Should Know
▶︎
Metastatic Breast Cancer: What You Need to Know
▶︎
2025 Best of Breast - Clinical Case Discussions: 1) Metastatic, ER+ Case; 2) HER2 Positive Case
▶︎
Breast Site Group Presentation: HER2-Low & HER2-UltraLow Metastatic Cancer - November 20, 2025
▶︎
Why NO Follow-Up Scans After Breast Cancer? The Truth About Imaging
▶︎
Clear Margins… But Risk Remains
▶︎
Targeted Therapy for HER2-low and HER2-ultralow Advanced Breast Cancer.
▶︎
Why Some Women Say No to Mammograms: The Hidden Dangers in Traditional Breast Cancer Screening
▶︎
What's the Best Diet for Hormone Receptor-Positive Breast Cancer? The Ultimate Guide for HR+
▶︎
Metastatic HR+/HER2- Breast Cancer Case | CDK4/6 Inhibitors, CNS Progression & Treatment Strategies
▶︎
Highlights - Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification
▶︎
Breast Cancer: Ductal Carcinoma in Situ (DCIS) EXPLAINED
▶︎